Skip to main content
. Author manuscript; available in PMC: 2023 Dec 1.
Published in final edited form as: Ann Intern Med. 2023 May 9;176(6):751–760. doi: 10.7326/M22-2751

Figure 3:

Figure 3:

Part A: Cumulative incidence of Major Adverse Cardiovascular and heart failure events among GLP1RA vs DPP4i users without cardiovascular disease.
timePoints 0 0.5 1 1.5 2 2.5 3 3.5
atRiskDPP4 28628 15476 9617 6398 4227 2816 1891 873
atRiskGLP1 28759 15534 9797 6408 4156 2756 1767 732
Part B: Cumulative incidence of Major Adverse Cardiovascular and heart failure events among SGLT2i vs DPP4i users without cardiovascular disease.
timePoints 0 0.5 1 1.5 2 2.5 3 3.5
atRiskDPP4 21170 9910 5188 3019 1762 1053 620 257
atRiskSGLT2 21200 9463 4670 2680 1394 748 357 125